How is the quality and supply of Pharmaceuticals guaranteed? The National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals.

On December 26, 2024, the National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals, inviting representatives from the National Medical Products Administration, selected Pharmaceutical enterprises, and research Institutions to communicate and exchange views on recent societal concerns regarding quality assurance of centrally procured Pharmaceuticals and innovative development in the Industry, and to listen to opinions and suggestions.

Zhitong FinanceDec 30, 2024 00:32 ET

Further Weakness as Sihuan Pharmaceutical Holdings Group (HKG:460) Drops 7.0% This Week, Taking Three-year Losses to 40%

Simply Wall StDec 19, 2024 19:10 ET

The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."

In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.

cls.cnDec 19, 2024 09:27 ET

Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.

The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.

Zhitong FinanceDec 16, 2024 01:21 ET

Beijing Centergate Technologies (000931.SZ): The company's Pharmaceutical has been included in the 2024 National Medical Insurance Directory.

On December 11, Gelonghui announced that Beijing Centergate Technologies (000931.SZ) stated that its wholly-owned subsidiary SIHUAN PHARM holds Beijing Huasu, ShanDong Huasu, and SIHUAN PHARM controlled Duoduo Pharmaceutical have a total of 34 products included in the "Medical Insurance Catalogue 2024." This includes products such as bisoprolol fumarate tablets, benidipine hydrochloride tablets, oxycodone hydrochloride tablets, and naloxone hydrochloride injection, which were originally included in the 2023 National Medical Insurance Catalogue. The selected products remain unchanged compared to the "Medical Insurance Catalogue 2023." The future sales situation of the included products may be affected by multiple factors such as changes in the market environment and will not impact the current operation of the company.

Gelonghui FinanceDec 11, 2024 05:09 ET

Bearish landing? Hong Kong stocks in the pharmaceutical sector collectively strengthen with wuxi apptec rising over 8%.

① How much impact did the biological safety legislation have on domestic pharmaceutical stocks previously? ② How do industry insiders view the subsequent development of the biological legislation?

cls.cnDec 8, 2024 21:40 ET